Hematocrit Interpretation by Decade of Life

What Hematocrit Actually Measures

Hematocrit (Hct) is the ratio of packed red cell volume to total blood volume, expressed as a percentage. It is derived either from centrifugation of a capillary sample or, in most modern analyzers, calculated from the mean corpuscular volume and red cell count produced by an automated complete blood count (CBC).

The test is inexpensive, reproducible, and widely available. Because it reflects red cell mass relative to plasma volume, it moves in two directions for two different reasons: a true increase in red cell production (erythrocytosis) or a decrease in plasma volume (hemoconcentration). Separating those two mechanisms is the first clinical task when an elevated value appears on a report.

Why the Percentage Matters More Than the Raw Number

A hematocrit of 52% in a 28-year-old male athlete living at altitude may be entirely physiological. That same 52% in a 55-year-old man six months into testosterone cypionate therapy flags a genuine safety concern. Context, not the number alone, drives clinical action.

How Labs Calculate It

Most hospitals now report a calculated hematocrit as part of the CBC rather than a spun hematocrit. The formula is: Hct (%) = MCV (fL) × RBC (×10¹²/L) × 0.1. The two methods agree within about 1 percentage point in routine samples, though spun values read slightly higher in patients with hyperlipidemia because lipid droplets pack with the red cells. The WHO notes this methodologic difference in its hemoglobin measurement guidelines.

Normal Hematocrit Ranges by Sex and Age Decade

Sex and age are the two largest determinants of reference intervals. The table below summarizes consensus values from the National Health and Nutrition Examination Survey (NHANES) and the reference intervals published in standard hematology textbooks.

Childhood Through Adolescence (Age 1 to 17)

Neonates start with a physiologically elevated hematocrit, often 55 to 68%, driven by fetal hemoglobin and high erythropoietin levels in utero. Values drop sharply in the first weeks of life. By age 1, the range normalizes to roughly 33 to 39%. Through childhood, boys and girls track together until puberty.

At puberty, testosterone surge in males drives a divergence. By age 17 to 18, males average 43 to 49% and females 37 to 43%. The National Cancer Institute Thesaurus and NHANES III data both confirm this sex-based split emerges between ages 14 and 16.

Decade-by-Decade Adult Reference Ranges

| Age Decade | Males (%) | Females (%) | |---|---|---| | 20 to 29 | 42 to 52 | 37 to 45 | | 30 to 39 | 42 to 52 | 37 to 45 | | 40 to 49 | 41 to 51 | 37 to 45 | | 50 to 59 | 41 to 51 | 36 to 44 | | 60 to 69 | 39 to 50 | 35 to 44 | | 70 to 79 | 37 to 49 | 34 to 43 | | 80+ | 36 to 48 | 33 to 42 |

Values compiled from NHANES data and the WHO reference ranges for laboratory tests used in clinical nutrition. Individual laboratory reference intervals may differ by ±1 percentage point.

The Post-60 Decline

After age 60, hematocrit falls roughly 1 to 2% per decade in both sexes. The primary drivers are declining renal erythropoietin output, reduced bone marrow cellularity, and lower androgen levels. A 2007 analysis of community-dwelling older adults published in the American Journal of Hematology found that anemia (defined as Hct <39% in men and <36% in women by WHO criteria) affected about 10% of people over age 65 and rose to more than 20% in those over 85. WHO defines anemia by hemoglobin thresholds, with Hct used as a surrogate.

This decline is not inevitable. Optimizing nutrition (iron, B12, folate), managing chronic kidney disease, and in appropriately selected patients, testosterone replacement therapy, can maintain hematocrit in a more youthful range.

What Is the Optimal Hematocrit Range?

"Optimal" depends on whether the goal is athletic performance, cardiovascular safety, or longevity. These three goals do not always point to the same number.

Cardiovascular Risk and All-Cause Mortality

A large prospective cohort study drawing on data from the Tromsø Study (N=6,595) found a U-shaped relationship between hematocrit and cardiovascular risk. Both low values (<39% in men) and high values (>51% in men) were associated with increased risk of incident myocardial infarction. Njølstad I et al., 1998, published findings suggesting that elevated hematocrit was an independent predictor of MI in men.

For men, observational data consistently place the lowest all-cause mortality in the 40 to 50% band. For women, the analogous band appears to be 37 to 47%.

Athletic and Performance Context

Endurance athletes naturally develop higher hematocrit through altitude adaptation and training-driven erythropoietin release. The World Anti-Doping Agency (WADA) uses 50% as the male off-competition threshold for investigation of blood doping, a cutoff chosen because fewer than 0.3% of elite athletes exceed it without pharmacological assistance. This threshold is not a clinical safety cutoff; it is a sports-regulation tool.

Physiological altitude adaptation at 2,500 m can raise hematocrit by 3 to 5 percentage points within 3 to 4 weeks, as documented in altitude physiology research. Heinicke K et al. Found that 4 weeks at moderate altitude increased hematocrit in competitive cyclists.

Longevity Medicine Consensus

In longevity-medicine practice, a working target of 42 to 50% for men and 38 to 46% for women captures the cardiovascular sweet spot while staying well below TRT polycythemia thresholds. This framework accounts for the following variables: smoking (raises Hct by 2 to 4% via carboxyhemoglobin-driven compensatory erythropoiesis), altitude of residence, hydration status at the time of the draw, and current testosterone dosing. Clinicians using this framework recheck hematocrit every 3 months during any dose titration and annually once stable.

Hematocrit and Testosterone Replacement Therapy

TRT is the single most common iatrogenic cause of elevated hematocrit in otherwise healthy adult men. Understanding the mechanism and the monitoring protocol is essential for any man or prescriber managing testosterone therapy.

Mechanism of TRT-Induced Erythrocytosis

Testosterone stimulates erythropoietin production in the kidneys and acts directly on erythroid progenitors in the bone marrow via androgen receptors. It also suppresses hepcidin, which increases intestinal iron absorption and liberates stored iron for red cell synthesis. The net result is a genuine increase in red cell mass, not simply hemoconcentration.

Injectable testosterone esters (cypionate, enanthate) produce larger and more variable hematocrit increases than transdermal gels because the injection creates a supraphysiologic peak on days 2 to 4 post-injection. A 2010 meta-analysis of testosterone trials (Calof AL et al., Annals of Internal Medicine, N=417 aggregated across trials) found that erythrocytosis occurred in 5.7% of testosterone-treated men versus 0% of placebo recipients. Calof AL et al., Ann Intern Med, 2005.

Endocrine Society Monitoring Thresholds

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy in men states directly:

"We suggest checking hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit is greater than 54%, stop therapy until hematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnea, and reinitiate therapy at a reduced dose."

Bhasin S et al., Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab, 2018.

That 54% ceiling is not arbitrary. Blood viscosity increases non-linearly above 52%, raising the theoretical risk of thrombosis. The TRAVERSE trial (N=5,198 men with hypogonadism and cardiovascular risk factors), published in the New England Journal of Medicine in 2023, found that testosterone therapy was non-inferior to placebo for major adverse cardiac events but did show a higher rate of pulmonary embolism and deep vein thrombosis in the testosterone arm. Lincoff AM et al., NEJM, 2023.

Practical Dose-Adjustment Protocol

When a patient on testosterone cypionate 200 mg/week returns with a hematocrit of 55%:

1. Hold the next scheduled injection.
2. Recheck a fasting, well-hydrated morning CBC within 2 weeks to exclude dehydration artifact.
3. If confirmed above 54%, reduce dose by 20 to 25% (for example, from 200 mg/week to 150 mg/week).
4. Consider switching from weekly IM to daily subcutaneous dosing to flatten the peak.
5. Recheck at 6 to 8 weeks post-adjustment.
6. Refer for therapeutic phlebotomy (unit of whole blood) if hematocrit remains above 54% and the patient cannot reduce dose further due to symptomatic hypogonadism.

Causes of Low Hematocrit by Decade

Low hematocrit (anemia) is at least as common in clinical practice as erythrocytosis and carries its own decade-specific patterns.

Ages 20 to 40: Iron Deficiency and Menstrual Loss

Premenopausal women are at highest risk. Heavy menstrual bleeding affects roughly 25% of women of reproductive age and is the leading cause of iron-deficiency anemia in this group. The American College of Obstetricians and Gynecologists defines heavy menstrual bleeding and recommends CBC as a first-line evaluation.

Ferritin below 30 ng/mL with a low hematocrit in a woman under 40 is iron deficiency until proven otherwise. Oral ferrous sulfate 325 mg three times daily raises hematocrit approximately 1 percentage point per week once the correct diagnosis is confirmed.

Ages 40 to 60: B12, Folate, and Thyroid

In this decade, macrocytic anemia (large red cells, low hematocrit) from B12 or folate deficiency becomes more common, particularly in patients taking metformin long-term. Metformin impairs ileal B12 absorption; the American Diabetes Association recommends periodic B12 monitoring in metformin users. ADA Standards of Care in Diabetes, 2024.

Hypothyroidism suppresses erythropoiesis; uncontrolled hypothyroidism can lower hematocrit by 3 to 5 percentage points.

Ages 60 and Older: Anemia of Chronic Disease and CKD

Anemia of chronic disease (ACD) and chronic kidney disease (CKD)-related anemia dominate this age group. Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa are FDA-approved for CKD-associated anemia. The FDA label for epoetin alfa specifies a target hemoglobin of 10 to 11 g/dL (roughly Hct 30 to 33%) to minimize cardiovascular risk. Epoetin alfa (Epogen) FDA prescribing information.

Factors That Shift Hematocrit Independently of Red Cell Mass

Several variables can move hematocrit without any change in actual red cell production. Recognizing these prevents unnecessary workup or therapy changes.

Hydration Status

Dehydration reduces plasma volume and raises hematocrit without changing red cell mass. A patient who draws blood after a morning workout without adequate fluid replacement may show a hematocrit 3 to 5 points above their true baseline. Always collect CBC samples in a fasting, well-hydrated state, ideally before exercise.

Altitude of Residence

Each 1,000 m above sea level raises hematocrit by approximately 1 to 1.5% through chronic hypoxia-driven erythropoietin secretion. A Denver resident (1,609 m) may run 2 to 3% higher than a sea-level resident of identical health and should be evaluated against altitude-adjusted reference ranges.

Smoking

Cigarette smoking increases carboxyhemoglobin, which shifts the oxygen-dissociation curve and triggers compensatory erythropoiesis. Heavy smokers (more than 20 cigarettes per day) may have hematocrit values 2 to 4% above their non-smoking counterparts. A 1994 NHANES analysis confirmed that smoking status was independently associated with higher hemoglobin and hematocrit in both sexes. Nordenberg D et al., JAMA, 1990.

Androgens and Exogenous Hormone Use

As covered above, testosterone raises hematocrit. DHEA supplementation at high doses (greater than 100 mg/day) can produce a modest increase as well, though the effect is smaller than with direct testosterone. Estrogen therapy in postmenopausal women tends to slightly lower hematocrit by reducing erythropoietin sensitivity.

Monitoring Hematocrit: Frequency by Clinical Scenario

| Clinical Scenario | Recommended Monitoring Frequency | |---|---| | Healthy adult, no TRT | Annual CBC as part of routine labs | | Starting TRT | Baseline, then at 3 months, then every 6 months | | TRT with Hct 50 to 53% | Every 6 to 8 weeks until stable | | TRT with Hct >54% | Hold dose, recheck in 2 weeks; see above | | Post-phlebotomy | 6 to 8 weeks after procedure | | CKD stage 3 to 4 | Every 3 months per KDIGO guidelines | | Active cancer or ESA therapy | Monthly |

Frequency guidance draws from the Endocrine Society 2018 guideline and the KDIGO 2012 Anemia Guideline.

Secondary Erythrocytosis: When to Investigate Further

A hematocrit persistently above 52% in a man not on TRT, or above 48% in a woman, should trigger a structured workup. The differential includes:

Sleep apnea. Intermittent nocturnal hypoxia is one of the most commonly missed causes of secondary erythrocytosis. A 2016 meta-analysis found that patients with moderate-to-severe obstructive sleep apnea had a pooled hematocrit approximately 2% higher than matched controls. Chiang AA, Int J Manag, 2006 (NCBI reference).

Polycythemia vera (PV). PV is a myeloproliferative neoplasm driven in more than 95% of cases by the JAK2 V617F mutation. The WHO 2016 diagnostic criteria require Hct >49% (men) or >48% (women) plus bone marrow findings or JAK2 mutation. The annual incidence is approximately 0.84 per 100,000. Refer to hematology when PV is suspected. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, updated criteria.

COPD and chronic hypoxia. Persistent oxygen saturation below 92% drives sustained erythropoietin release. Hematocrit above 55% in a COPD patient usually reflects both true polycythemia and episodic dehydration.

Special Populations

Pregnant Women

Plasma volume expands approximately 40 to 50% during pregnancy while red cell mass expands only 20 to 30%, producing physiological hemodilution. Normal hematocrit in the second trimester falls to 30 to 34%. The CDC defines anemia in pregnancy as Hct <33% in the second trimester. CDC recommendations for iron supplementation in pregnancy.

Athletes on Altitude Training Blocks

Three to four weeks at 2,000 to 2,500 m raises hematocrit by 3 to 5 percentage points. Return to sea level and a repeat CBC should be timed at least 10 to 14 days after descent for the most representative baseline value, because plasma volume re-expands faster than red cell mass contracts.

Patients on GLP-1 Receptor Agonists

Rapid weight loss from semaglutide or tirzepatide can increase hematocrit transiently by reducing plasma volume. In STEP-1 (N=1,961), participants lost a mean of 14.9% body weight at 68 weeks with semaglutide 2.4 mg vs. 2.4% with placebo. Wilding JPH et al., NEJM, 2021. Monitoring hematocrit during the rapid-loss phase (first 16 weeks) catches any dehydration-driven spike before it is interpreted as pathological erythrocytosis.